Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Immunogenetics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1460318
This article is part of the Research Topic Immunopathology of Non-Infectious Inflammatory Diseases: Focus on Genetics and Epigenetics View all articles

Genomic Insight into COVID-19 Severity in MAFLD Patients: A Single-Center Prospective Cohort Study

Provisionally accepted
Mykhailo Buchynskyi Mykhailo Buchynskyi 1Valentyn Oksenych Valentyn Oksenych 2*Iryna Kamyshna Iryna Kamyshna 1Olena Budarna Olena Budarna 1Iryna Halabitska Iryna Halabitska 1Pavlo Petakh Pavlo Petakh 3*Oleksandr Kamyshnyi Oleksandr Kamyshnyi 1*
  • 1 Ternopil State Medical University, Ternopil, Ternopil Oblast, Ukraine
  • 2 University of Bergen, Bergen, Hordaland, Norway
  • 3 Uzhhorod National University, Uzhhorod, Ukraine

The final, formatted version of the article will be published soon.

    This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes associated with the interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity and their association with nonalcoholic fatty liver disease (MAFLD). We did not observe a significant association between the investigated SNPs and COVID-19 severity. While the IFNAR2 rs2236757 A allele was correlated with higher creatinine levels upon admission and the G allele was correlated with lower band neutrophils upon discharge, these findings require further investigation. The distribution of OAS gene polymorphisms (rs10774671 and rs10735079) did not differ between MAFLD patients and non-MAFLD patients. Our study population's distribution of ACE2 rs2074192 genotypes and alleles differed from that of the European reference population. Overall, our findings suggest that these specific SNPs may not be major contributors to COVID-19 severity in our patient population, highlighting the potential role of other genetic factors and environmental influences.

    Keywords: MAFLD, COVID-19, ACE2, IFNAR2, SNP

    Received: 05 Jul 2024; Accepted: 23 Aug 2024.

    Copyright: © 2024 Buchynskyi, Oksenych, Kamyshna, Budarna, Halabitska, Petakh and Kamyshnyi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Valentyn Oksenych, University of Bergen, Bergen, 5020, Hordaland, Norway
    Pavlo Petakh, Uzhhorod National University, Uzhhorod, Ukraine
    Oleksandr Kamyshnyi, Ternopil State Medical University, Ternopil, 46002, Ternopil Oblast, Ukraine

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.